Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06821386

N-Care Project: Enhancing Asian-Pacific Collaboration

Through Asian-Pacific multinational collaboration, we aim to utilize third-generation genome sequencing to rapidly diagnose genetic diseases in critically ill infants and young children, achieving the goal of early diagnosis for targeted treatment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 18 month

Sex eligibility

All sexes

Study type

Observational

Primary location

National Taiwan University Hospital

Taipei, Taiwan

Location status: Recruiting

Location contact

Ni-Chung Lee, PhD

CONTACT

[email protected]

+886-23123456 ext. 271936

About this study

A group of individuals with specific characteristics was selected. Genetic studies were arranged for participants who provided their consent.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: infant/newborn less than 18 months
  • Admitted to intensive care unit
  • At least one of the following conditions A. Specific anomaly highly suggestive of a genetic etiology
  • Multiple birth defects
  • Single major malformation that required intervention (surgery or medication)
  • Significantly abnormal EKG
  • Significant hypotonia

B. Children with high-risk stratification on assessment of a Brief Resolved Unexplained Event (BRUE) with any of the following:

  • Recurrent severe infection events
  • Recurrent or prolonged seizures
  • Unexplained cardiopulmonary resuscitation (CPR)
  • Suspect inborn error of metabolism

Exclusion criteria

  • Infants with a definitive non-genetic diagnosis: ex as below A. An infection with normal response to therapy B. Isolated prematurity C. Transient hypoglycemia D. Isolated unconjugated hyperbilirubinemia E. Isolated Transient Neonatal Tachypnea F. Those where the clinical course can be explained without genetic testing
  • Confirmed genetic diagnosis explains illness
  • Lack of consent: Families who do not consent to genetic testing or data sharing.
  • Infants without sufficient DNA sample quality/quantity: Where the quality or quantity of the DNA sample is inadequate for sequencing.

Treatment and study plan

Genetic study with nanopore sequencing

Diagnostic Test

The study targets critically ill children under 18 months of age, employing third-generation genome sequencing technology to complete long-read sequencing within 8-11 days, analyzing single nucleotide variants, small insertions/deletions, and structural variations. Through this research, we aim to enhance diagnostic accuracy, enabling ICUs to provide personalized and precision care and treatment based on genetic information, thereby ensuring a greater level of health security for these children. We only draw 3-5cc whole blood once for exam.

Primary outcomes

  1. Positive yield rate

    Time frame: 9 days after enrollment

    The percentage of individuals who test positive among the long-read sequencing exam

Study contacts

Contact information is provided by the study sponsor or research team.

Ni-Chung Lee, MDPhD

CONTACT

[email protected]

+886-2-23123456 ext. 271936

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Acronym: N-Care project

Important dates

Study start
2025
Primary completion
2025
Study completion
2032
First posted
Feb 12, 2025
Registry last updated
Feb 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.